Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer.

Wedam S, Fashoyin-Aje L, Gao X, Bloomquist E, Tang S, Sridhara R, Goldberg KB, King-Kallimanis BL, Theoret MR, Ibrahim A, Amiri-Kordestani L, Pazdur R, Beaver JA.

Clin Cancer Res. 2020 Mar 26. pii: clincanres.3980.2019. doi: 10.1158/1078-0432.CCR-19-3980. [Epub ahead of print]

PMID:
32217612
2.

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results.

Shore N, Kaplan SA, Tutrone R, Levin R, Bailen J, Hay A, Kalota S, Bidair M, Freedman S, Goldberg K, Snoy F, Epstein JI.

World J Urol. 2020 Feb 22. doi: 10.1007/s00345-020-03127-w. [Epub ahead of print]

PMID:
32088746
3.

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R.

Oncologist. 2020 Feb;25(2):e328-e334. doi: 10.1634/theoncologist.2019-0627. Epub 2019 Oct 22.

4.

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1.

Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, Tang S, Xu Y, Liu J, Fu W, Song P, King-Kallimanis BL, Hou S, Gong Y, Kalavar S, Ghosh S, Philip R, Goldberg KB, Theoret MR, Blumenthal GM, Kluetz PG, Sridhara R, Pazdur R, Beaver JA.

Clin Cancer Res. 2020 Jan 30. pii: clincanres.3545.2019. doi: 10.1158/1078-0432.CCR-19-3545. [Epub ahead of print]

PMID:
32001481
5.

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM.

Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16.

PMID:
31859246
6.

Relapse of operant behavior after response elimination with an extinction or an omission contingency.

Rey CN, Thrailkill EA, Goldberg KL, Bouton ME.

J Exp Anal Behav. 2020 Jan;113(1):124-140. doi: 10.1002/jeab.568. Epub 2019 Dec 13.

PMID:
31835280
7.

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.

Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, Theoret MR, Amiri-Kordestani L, Pazdur R, Beaver JA.

Clin Cancer Res. 2020 Mar 15;26(6):1208-1212. doi: 10.1158/1078-0432.CCR-19-2580. Epub 2019 Oct 24.

PMID:
31649043
8.

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R.

Oncologist. 2019 Oct 22. pii: theoncologist.2019-0627. doi: 10.1634/theoncologist.2019-0627. [Epub ahead of print]

9.

Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.

Howie LJ, Singh H, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, Sridhara R, Sanchez J, Prowell TM, Kluetz PG, King-Kallimanis BL, Gao JJ, Ibrahim A, Goldberg KB, Theoret M, Pazdur R, Beaver JA.

J Clin Oncol. 2019 Dec 20;37(36):3475-3483. doi: 10.1200/JCO.18.02217. Epub 2019 Sep 27.

PMID:
31560580
10.

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2020 Feb 1;26(3):532-536. doi: 10.1158/1078-0432.CCR-19-2329. Epub 2019 Sep 23.

PMID:
31548341
11.

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.

Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA.

J Urol. 2020 Jan;203(1):115-119. doi: 10.1097/JU.0000000000000532. Epub 2019 Sep 10.

PMID:
31502940
12.

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.

Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, Przepiorka D, Namuswe F, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2020 Jan 15;26(2):328-331. doi: 10.1158/1078-0432.CCR-19-1255. Epub 2019 Aug 23.

PMID:
31444252
13.

Applying machine learning to predict future adherence to physical activity programs.

Zhou M, Fukuoka Y, Goldberg K, Vittinghoff E, Aswani A.

BMC Med Inform Decis Mak. 2019 Aug 22;19(1):169. doi: 10.1186/s12911-019-0890-0.

14.

Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.

Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA.

Eur Urol Oncol. 2019 Jul;2(4):397-404. doi: 10.1016/j.euo.2018.08.022. Epub 2018 Sep 20.

PMID:
31277776
15.

Experimental and Computational Investigation of the Aerobic Oxidation of a Late Transition Metal-Hydride.

Wright AM, Pahls DR, Gary JB, Warner T, Williams JZ, M Knapp SM, Allen KE, Landis CR, Cundari TR, Goldberg KI.

J Am Chem Soc. 2019 Jul 10;141(27):10830-10843. doi: 10.1021/jacs.9b04706. Epub 2019 Jul 1.

PMID:
31259542
16.

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.

Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J, Goldberg KB, Sridhara R, Ibrahim A, Theoret M, Beaver JA, Pazdur R.

J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22.

PMID:
31116675
17.

Hydrogenolysis of Dinuclear PCNR Ligated PdII μ-Hydroxides and Their Mononuclear PdII Hydroxide Analogues.

Bailey WD, Phearman AS, Luconi L, Rossin A, Yakhvarov DG, D'Accolti L, Flowers SE, Kaminsky W, Kemp RA, Giambastiani G, Goldberg KI.

Chemistry. 2019 Jul 25;25(42):9920-9929. doi: 10.1002/chem.201900507. Epub 2019 Jul 3.

PMID:
31090244
18.

Depression in Deaf and Hard of Hearing Youth.

Dreyzehner J, Goldberg KA.

Child Adolesc Psychiatr Clin N Am. 2019 Jul;28(3):411-419. doi: 10.1016/j.chc.2019.02.011. Epub 2019 Apr 4. Review.

PMID:
31076117
19.

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.

Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, Shen YL, Sheth CM, Liu C, Leong R, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2019 Oct 15;25(20):6021-6025. doi: 10.1158/1078-0432.CCR-19-0365. Epub 2019 May 7.

PMID:
31064779
20.

Electrophilic Organoiridium(III) Pincer Complexes on Sulfated Zirconia for Hydrocarbon Activation and Functionalization.

Syed ZH, Kaphan DM, Perras FA, Pruski M, Ferrandon MS, Wegener EC, Celik G, Wen J, Liu C, Dogan F, Goldberg KI, Delferro M.

J Am Chem Soc. 2019 Apr 17;141(15):6325-6337. doi: 10.1021/jacs.9b00896. Epub 2019 Apr 5.

PMID:
30900885
21.

Goals of Care: Development and Use of the Serious Veterinary Illness Conversation Guide.

Goldberg KJ.

Vet Clin North Am Small Anim Pract. 2019 May;49(3):399-415. doi: 10.1016/j.cvsm.2019.01.006. Epub 2019 Mar 7. Review.

PMID:
30853241
22.

Advances in Palliative Medicine.

Goldberg KJ.

Vet Clin North Am Small Anim Pract. 2019 May;49(3):xiii-xv. doi: 10.1016/j.cvsm.2019.02.001. Epub 2019 Mar 7. No abstract available.

PMID:
30853240
23.

Current Topics in Serious Illness and Palliative Medicine: A Curricular Initiative in a US Veterinary Teaching Institution.

Goldberg KJ.

Vet Clin North Am Small Anim Pract. 2019 May;49(3):373-386. doi: 10.1016/j.cvsm.2019.01.005. Epub 2019 Mar 7. Review.

PMID:
30853239
24.

Acid-Mediated Ring Expansion of 2,2-Disubstituted Azetidine Carbamates to 6,6-Disubstituted 1,3-Oxazinan-2-ones.

Boddy AJ, Cordier CJ, Goldberg K, Madin A, Spivey AC, Bull JA.

Org Lett. 2019 Mar 15;21(6):1818-1822. doi: 10.1021/acs.orglett.9b00407. Epub 2019 Mar 4.

25.

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.

Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR, Pazdur R.

Ann Oncol. 2019 May 1;30(5):830-838. doi: 10.1093/annonc/mdz060.

PMID:
30796424
26.

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28.

PMID:
30692099
27.

Impact of Hemolysis on Acute Kidney Injury and Mortality in Children Supported with Cardiac Extracorporeal Membrane Oxygenation.

Borasino S, Kalra Y, Elam AR, Carlisle O'Meara L, Timpa JG, Goldberg KG, Collins Gaddis JL, Alten JA.

J Extra Corpor Technol. 2018 Dec;50(4):217-224.

28.

FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.

Howie LJ, Scher NS, Amiri-Kordestani L, Zhang L, King-Kallimanis BL, Choudhry Y, Schroeder J, Goldberg KB, Kluetz PG, Ibrahim A, Sridhara R, Blumenthal GM, Pazdur R, Beaver JA.

Clin Cancer Res. 2019 May 15;25(10):2949-2955. doi: 10.1158/1078-0432.CCR-18-3003. Epub 2018 Dec 14.

PMID:
30552112
29.

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.

Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA.

Oncologist. 2019 Apr;24(4):563-569. doi: 10.1634/theoncologist.2018-0084. Epub 2018 Dec 12.

30.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.

Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, Janoria KG, Gieser G, Bateman DA, Przepiorka D, Shen YL, Shord SS, Sheth CM, Banerjee A, Liu J, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.

PMID:
30541745
31.

Examining Commonly Reported Sex Trafficking Indicators From Practitioners' Perspectives: Findings From a Pilot Study.

Gerassi LB, Nichols AJ, Cox A, Goldberg KK, Tang C.

J Interpers Violence. 2018 Nov 28:886260518812813. doi: 10.1177/0886260518812813. [Epub ahead of print]

PMID:
30484358
32.

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN.

Urol Oncol. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. Epub 2018 Nov 13.

PMID:
30446460
33.

Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers.

Costa DN, Xi Y, Aziz M, Passoni N, Shakir N, Goldberg K, Francis F, Roehrborn CG, Leon AD, Pedrosa I.

AJR Am J Roentgenol. 2019 Jan;212(1):109-116. doi: 10.2214/AJR.18.19937. Epub 2018 Nov 1.

PMID:
30383404
34.

The Unexpected Essentiality of glnA2 in Mycobacterium smegmatis Is Salvaged by Overexpression of the Global Nitrogen Regulator glnR, but Not by L-, D- or Iso-Glutamine.

Rakovitsky N, Bar Oz M, Goldberg K, Gibbons S, Zimhony O, Barkan D.

Front Microbiol. 2018 Sep 11;9:2143. doi: 10.3389/fmicb.2018.02143. eCollection 2018.

35.

Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.

Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y.

J Med Chem. 2018 Oct 11;61(19):8797-8810. doi: 10.1021/acs.jmedchem.8b00938. Epub 2018 Sep 24.

PMID:
30204441
36.

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

Barlaam B, Cadogan E, Campbell A, Colclough N, Dishington A, Durant S, Goldberg K, Hassall LA, Hughes GD, MacFaul PA, McGuire TM, Pass M, Patel A, Pearson S, Petersen J, Pike KG, Robb G, Stratton N, Xin G, Zhai B.

ACS Med Chem Lett. 2018 Jul 13;9(8):809-814. doi: 10.1021/acsmedchemlett.8b00200. eCollection 2018 Aug 9.

37.

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.

Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R.

Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17.

38.

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.

Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, Goldberg KB, McKee AE, Kaminskas E, Farrell A, Pazdur R.

Oncologist. 2018 Dec;23(12):1520-1524. doi: 10.1634/theoncologist.2018-0295. Epub 2018 Aug 17.

39.

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.

Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, McKee AE, Pazdur R.

Oncologist. 2018 Nov;23(11):1366-1371. doi: 10.1634/theoncologist.2018-0179. Epub 2018 Jul 17.

40.

The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment.

Goldberg KB, Blumenthal GM, Pazdur R.

Cancer J. 2018 May/Jun;24(3):131-135. doi: 10.1097/PPO.0000000000000316. Review.

PMID:
29794538
41.

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.

Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.

42.

Description, evaluation and scale-up potential of a model for rapid access to early intervention for psychosis.

MacDonald K, Malla A, Joober R, Shah JL, Goldberg K, Abadi S, Doyle M, Iyer SN.

Early Interv Psychiatry. 2018 Dec;12(6):1222-1228. doi: 10.1111/eip.12564. Epub 2018 Mar 26.

PMID:
29582562
43.

Baby or bathwater? Referrals of "non-cases" in a targeted early identification intervention for psychosis.

Jordan G, Kinkaid M, Iyer SN, Joober R, Goldberg K, Malla A, Shah JL.

Soc Psychiatry Psychiatr Epidemiol. 2018 Jul;53(7):757-761. doi: 10.1007/s00127-018-1502-5. Epub 2018 Mar 14.

PMID:
29541798
44.

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.

Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R.

J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.

45.

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.

Beaver JA, Howie LJ, Pelosof L, Kim T, Liu J, Goldberg KB, Sridhara R, Blumenthal GM, Farrell AT, Keegan P, Pazdur R, Kluetz PG.

JAMA Oncol. 2018 Jun 1;4(6):849-856. doi: 10.1001/jamaoncol.2017.5618. Review.

PMID:
29494733
46.

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.

Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT, Pazdur R.

Oncologist. 2018 Jun;23(6):734-739. doi: 10.1634/theoncologist.2017-0440. Epub 2018 Feb 7.

47.

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.

Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, Bijwaard K, Lee EY, Philip R, Jiang X, Rodriguez L, McKee AE, Keegan P, Pazdur R.

Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.

48.

FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, Yu J, Zhao P, Palmby TR, Goldberg KB, Chang CJG, Patel P, Alebachew E, Tilley A, Pierce WF, Ibrahim A, Blumenthal GM, Sridhara R, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Jul 1;24(13):2999-3004. doi: 10.1158/1078-0432.CCR-17-2369. Epub 2018 Feb 7.

49.

Objectively Measured Baseline Physical Activity Patterns in Women in the mPED Trial: Cluster Analysis.

Fukuoka Y, Zhou M, Vittinghoff E, Haskell W, Goldberg K, Aswani A.

JMIR Public Health Surveill. 2018 Feb 1;4(1):e10. doi: 10.2196/publichealth.9138.

50.

Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.

Pelosof L, Lemery S, Casak S, Jiang X, Rodriguez L, Pierre V, Bi Y, Liu J, Zirkelbach JF, Patel A, Goldberg KB, McKee AE, Keegan P, Pazdur R.

Oncologist. 2018 Apr;23(4):496-500. doi: 10.1634/theoncologist.2017-0422. Epub 2018 Jan 31.

Supplemental Content

Loading ...
Support Center